AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied SetbackInvestors Business Daily • 11/22/24
My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 BuysSeeking Alpha • 11/20/24
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer's Transgenic MiceBusiness Wire • 11/19/24
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian CancerPRNewsWire • 11/18/24
Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's ProspectsSeeking Alpha • 11/14/24
RFK Jr's appointment in health could accelerate psychedelic drug development, analysts sayProactive Investors • 11/12/24
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology PortfolioBenzinga • 11/12/24
AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts sayMarket Watch • 11/12/24